ABSTRACT
ZBP1 is an interferon-induced cytosolic nucleic acid sensor that facilitates antiviral responses via RIPK3. Although ZBP1-mediated programmed cell death is widely described, whether and how it promotes inflammatory signaling is unclear. Here, we report a ZBP1-induced inflammatory signaling pathway mediated by K63- and M1-linked ubiquitin chains, which depends on RIPK1 and RIPK3 as scaffolds independently of cell death. In human HT29 cells, ZBP1 associated with RIPK1 and RIPK3 as well as ubiquitin ligases cIAP1 and LUBAC. ZBP1-induced K63- and M1-linked ubiquitination of RIPK1 and ZBP1 to promote TAK1- and IKK-mediated inflammatory signaling and cytokine production. Inhibition of caspase activity suppressed ZBP1-induced cell death but enhanced cytokine production in a RIPK1- and RIPK3 kinase activity-dependent manner. Lastly, we provide evidence that ZBP1 signaling contributes to SARS-CoV-2-induced cytokine production. Taken together, we describe a ZBP1-RIPK3-RIPK1-mediated inflammatory signaling pathway relayed by the scaffolding role of RIPKs and regulated by caspases, which may induce inflammation when ZBP1 is activated below the threshold needed to trigger a cell death response.
Subject(s)
Cell Death , RNA-Binding Proteins , Receptor-Interacting Protein Serine-Threonine Kinases , Humans , Cytokines , Receptor-Interacting Protein Serine-Threonine Kinases/genetics , Signal Transduction , Ubiquitin , RNA-Binding Proteins/genetics , HT29 Cells , InflammationABSTRACT
Epstein-Barr virus (EBV) was the first human tumor virus being discovered and remains to date the only human pathogen that can transform cells in vitro. 55 years of EBV research have now brought us to the brink of an EBV vaccine. For this purpose, recombinant viral vectors and their heterologous prime-boost vaccinations, EBV-derived virus-like particles and viral envelope glycoprotein formulations are explored and are discussed in this review. Even so, cell-mediated immune control by cytotoxic lymphocytes protects healthy virus carriers from EBV-associated malignancies, antibodies might be able to prevent symptomatic primary infection, the most likely EBV-associated pathology against which EBV vaccines will be initially tested. Thus, the variety of EBV vaccines reflects the sophisticated life cycle of this human tumor virus and only vaccination in humans will finally be able to reveal the efficacy of these candidates. Nevertheless, the recently renewed efforts to develop an EBV vaccine and the long history of safe adoptive T cell transfer to treat EBV-associated malignancies suggest that this oncogenic γ-herpesvirus can be targeted by immunotherapies. Such vaccination should ideally implement the very same immune control that protects healthy EBV carriers.
Subject(s)
Epstein-Barr Virus Infections/prevention & control , Herpesvirus 4, Human/immunology , Herpesvirus Vaccines/therapeutic use , Animals , Antibodies, Neutralizing/immunology , Epstein-Barr Virus Infections/immunology , Herpesvirus Vaccines/immunology , Humans , Vaccination , Vaccines, Virus-Like Particle/immunology , Vaccines, Virus-Like Particle/therapeutic use , Viral Envelope Proteins/immunology , Viral Envelope Proteins/therapeutic useABSTRACT
DEC-205 is a type I transmembrane multilectin receptor that is predominantly expressed on dendritic cells (DCs). Therefore, previous studies primarily focused on processing of DEC-205targeted antigens by this potent antigen presenting cell type. Here we show that Epstein-Barr virus (EBV) transformed lymphoblastoid B-cell lines (LCLs) not only express DEC-205 at similar levels to DCs, but also efficiently present targeted EBV nuclear antigen 1 (EBNA1) and EBV-latent membrane protein 1 (LMP1) to EBNA1- and LMP1-specific CD4+ and CD8+ T-cell clones in vitro. Targeting of antigens to DEC-205 on B cells led to more efficient MHC class II than I loading, and stimulated T cells more efficiently than targeting to DEC-205 on DCs. Although LCLs internalized DEC-205targeted antigens less efficiently than DCs, they retained them for longer time periods and delivered them to endosomal compartments that receive also B-cell receptor targeted proteins. This could facilitate prolonged T-cell stimulation and efficient MHC class II loading, and, indeed, CD4+ T-cell expansion by DEC-205targeted vaccination was significantly compromised in B-cell deficient mice. These studies suggest that B cells, activated by virus transformation or other means, can contribute to T-cell stimulation after DEC-205 targeting of antigens during vaccination.
Subject(s)
Antigens, CD/metabolism , B-Lymphocytes/immunology , B-Lymphocytes/virology , Dendritic Cells/immunology , Herpesvirus 4, Human/physiology , Lectins, C-Type/metabolism , Receptors, Cell Surface/metabolism , T-Lymphocytes/immunology , Animals , Antigen Presentation/physiology , Antigens, CD/immunology , B-Lymphocytes/metabolism , Cell Line, Transformed , Cell Transformation, Viral/immunology , Cells, Cultured , Dendritic Cells/physiology , Herpesvirus 4, Human/immunology , Lectins, C-Type/immunology , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Minor Histocompatibility Antigens , Molecular Targeted Therapy , Receptors, Antigen, B-Cell/immunology , Receptors, Antigen, B-Cell/metabolism , Receptors, Cell Surface/immunology , T-Lymphocytes/metabolism , T-Lymphocytes/physiology , Vaccination/methodsABSTRACT
Functional differences between human dendritic cell (DC) subsets and the potential benefits of targeting them with vaccines remain poorly defined. Here we describe that mice with reconstituted human immune system components (huNSG mice) develop all human conventional and plasmacytoid DC compartments in lymphoid organs. Testing different Toll-like receptor agonists for DC maturation in vivo, we found that IL-12p70 and interferon (IFN)-α production correlated with the maturation of CD141+ (BDCA3+) conventional DCs in huNSG mice. Furthermore, depletion of CD141+ DCs before stimulation significantly reduced IFN-α levels in vivo. This DC subset produced similar total amounts but different subtypes of IFN-α in response to synthetic double-stranded RNA compared with plasmacytoid DCs in response to a single-stranded RNA equivalent. Moreover, synthetic double-stranded RNA as adjuvant and antigen targeting to the endocytic receptor DEC-205, a combination that focuses antigen presentation for T-cell priming on CD141+ DCs, stimulated antigen-specific human CD4+ T-cell responses. Thus, the human CD141+ DC subset is a prominent source of IFN-α and interleukin-12 production and should be further evaluated for vaccine development.
Subject(s)
Antigens, CD/immunology , Dendritic Cells/immunology , Interferon-alpha/biosynthesis , Lectins, C-Type/immunology , Lymphocyte Activation/immunology , RNA, Double-Stranded/immunology , Receptors, Cell Surface/immunology , Animals , Antigen Presentation/immunology , CD8-Positive T-Lymphocytes/immunology , Dendritic Cells/cytology , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Interferon-alpha/immunology , Mice , Minor Histocompatibility AntigensABSTRACT
Evasion of immune T cell responses is crucial for persistent viruses to establish a normal carrier state. Most studies on active immune modulation mechanisms have focused on the stage of virus production in infected cells, when large numbers of viral antigens and potential immune modulators are expressed. For oncogenic viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV), which is carried as a lifelong infection, usually with little harmful effect, but can cause various tumors, the immune evasion strategies can also be relevant in the context of tumorigenesis. Here we report that the virus-encoded interferon regulatory factor 3 (vIRF3) latent viral gene expressed in KSHV-related tumors functions as a potent immunevasin. Expression of vIRF3 downregulates surface major histocompatibility complex class II (MHC-II) DR expression with slow kinetics but, more importantly, can substantially inhibit recognition by KSHV-specific CD4 T cells prior to its effects on MHC-II DR downregulation in model cell systems. This property of vIRF3 is only partly due to its ability to inhibit the transcription of CIITA and, thus, MHC-II expression; CIITA-independent inhibition of MHC-II transcripts and another as yet unidentified posttranscriptional mechanism are also involved in qualitatively modulating the availability of specific peptide/MHC-II complexes at the cell surface. Consistent with these observations, the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are generally resistant to recognition by KSHV-specific CD4 T cells. Interestingly, some PEL lines exhibit small subpopulations with lower vIRF3 expression that can be recognized. These data implicate vIRF3 as a critical determinant of the MHC-II antigen presentation function in KSHV-associated PELs that is likely to be important in the pathogenesis of these tumors.
Subject(s)
Antigen Presentation , Herpesvirus 8, Human/pathogenicity , Histocompatibility Antigens Class II/metabolism , Host-Pathogen Interactions , Immune Evasion , Interferon Regulatory Factors/metabolism , Trans-Activators/antagonists & inhibitors , Viral Proteins/metabolism , Cell Transformation, Neoplastic , Down-Regulation , Herpesvirus 8, Human/immunology , Histocompatibility Antigens Class II/biosynthesis , Histocompatibility Antigens Class II/immunology , HumansABSTRACT
Whereas exogenously acquired proteins are the major source of antigens feeding the MHC class II pathway in antigen-presenting cells, some endogenously expressed antigens also access that pathway but the rules governing such access are poorly understood. Here we address this using Epstein-Barr virus (EBV)-coded nuclear antigen EBNA1, a protein naturally expressed in EBV-infected B lymphoblastoid cell lines (LCLs) and a source of multiple CD4(+) T cell epitopes. Using CD4(+) T cell clones against three indicator epitopes, we find that two epitopes are weakly displayed on the LCL surface whereas the third is undetectable, a pattern of limited epitope presentation that is maintained even when nuclear expression of EBNA1 is induced to high supraphysiological levels. Inhibitor and siRNA studies show that, of the two epitopes weakly presented under these conditions, one involves macroautophagy, and the second involves antigen delivery to the MHC II pathway by another endogenous route. In contrast, when EBNA1 is expressed as a cytoplasmic protein, all three CD4 epitopes are processed and presented much more efficiently, and all involve macroautophagy. We conclude that EBNA1's nuclear location limits its accessibility to the macroautophagy pathway and, in consequence, limits the level and range of EBNA1 CD4 epitopes naturally displayed on the infected cell surface.
Subject(s)
Autophagy/immunology , CD4 Antigens/metabolism , Epstein-Barr Virus Nuclear Antigens/metabolism , Antigen Presentation , B-Lymphocytes/cytology , B-Lymphocytes/immunology , B-Lymphocytes/virology , Cell Line , Cell Nucleus/immunology , Cell Nucleus/virology , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/metabolism , Epstein-Barr Virus Nuclear Antigens/genetics , HLA-DR Antigens/metabolism , Herpesvirus 4, Human/immunology , HumansABSTRACT
Many pathogens relevant to human disease do not infect other animal species. Therefore, animal models that reconstitute or harbor human tissues are explored as hosts for these. In this review, we will summarize recent advances to utilize mice with human immune system components, reconstituted from hematopoietic progenitor cells in vivo. Such mice can be used to study human pathogens that replicate in leukocytes. In addition to studying the replication of these pathogens, the reconstituted human immune system components can also be analyzed for initiating immune responses and control against these infections. Moreover, these new animal models of human infectious disease should replicate the reactivity of the human immune system to vaccine candidates and, especially, the adjuvants contained in them, more faithfully.
Subject(s)
Immune System/immunology , Adaptive Immunity/immunology , Animals , Humans , Immunity, Innate/immunology , Mice , Models, Animal , VaccinationABSTRACT
Viruses that naturally infect cells expressing both MHC I and MHC II molecules render themselves potentially visible to both CD8+ and CD4+ T cells through the de novo expression of viral antigens. Here we use one such pathogen, the B-lymphotropic Epstein-Barr virus (EBV), to examine the kinetics of these processes in the virally-infected cell, comparing newly synthesised polypeptides versus the mature protein pool as viral antigen sources for MHC I- and MHC II-restricted presentation. EBV-transformed B cell lines were established in which the expression of two cognate EBV antigens, EBNA1 and EBNA3B, could be induced and then completely suppressed by doxycycline-regulation. These cells were used as targets for CD8+ and CD4+ T cell clones to a range of EBNA1 and EBNA3B epitopes. For both antigens, when synthesis was induced, CD8 epitope display rose quickly to near maximum within 24 h, well before steady state levels of mature protein had been reached, whereas CD4 epitope presentation was delayed by 36-48 h and rose only slowly thereafter. When antigen expression was suppressed, despite the persistence of mature protein, CD8 epitope display fell rapidly at rates similar to that seen for the MHC I/epitope half-life in peptide pulse-chase experiments. By contrast, CD4 epitope display persisted for many days and, following peptide stripping, recovered well on cells in the absence of new antigen synthesis. We infer that, in virally-infected MHC I/II-positive cells, newly-synthesised polypeptides are the dominant source of antigen feeding the MHC I pathway, whereas the MHC II pathway is fed by the mature protein pool. Hence, newly-infected cells are rapidly visible only to the CD8 response; by contrast, latent infections, in which viral gene expression has been extinguished yet viral proteins persist, will remain visible to CD4+ T cells.
Subject(s)
Antigens, Viral/immunology , Epstein-Barr Virus Infections/immunology , Herpesvirus 4, Human/immunology , T-Lymphocytes/immunology , Antigen Presentation , B-Lymphocytes , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Epitopes/immunology , Humans , Time Factors , Viral ProteinsABSTRACT
The Epstein-Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available. We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EBV (EBNA1), either targeted to the DEC205 receptor on DCs or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector, improved priming of antigen-specific CD4+ T cell help. This help supported the expansion and maintenance of EBNA1-specific CD8+ T cells that are most efficiently primed by recombinant adenoviruses that encode EBNA1. These combined CD4+ and CD8+ T cell responses protected against EBNA1-expressing T and B cell lymphomas, including lymphoproliferations that emerged spontaneously after EBNA1 expression. In particular, the heterologous EBNA1-expressing adenovirus, boosted by EBNA1-encoding MVA vaccination, demonstrated protection as a prophylactic and therapeutic treatment for the respective lymphoma challenges. Our study shows that such heterologous prime-boost vaccinations against EBV-associated malignancies as well as symptomatic primary EBV infection should be further explored for clinical development.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/immunology , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Nuclear Antigens/immunology , Lymphoma/therapy , Animals , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/cytology , Cell Line, Tumor , Epstein-Barr Virus Infections/complications , Genetic Vectors , HEK293 Cells , Herpesvirus 4, Human , Humans , Immunoglobulin G/chemistry , Interferon-gamma/immunology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Lymphoma/immunology , Lymphoma/virology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Rats , Treatment Outcome , Vaccination , Vaccinia virus/immunologyABSTRACT
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal antigen expressed on multiple tumors and has no significant expression on normal human tissues. ROR1 is highly upregulated in chronic lymphocytic leukemia (CLL) B cells. NOD-scid IL2rg-/- (NSG) mice engrafted with human CD34+ hematopoietic progenitor cells (huNSG) achieved multilineage human immune cell reconstitution including B cells, T cells, NK cells, and DCs. Like the CLL patients, huNSG mice have abnormally high percentage of CD5-expressing B cells in the periphery. In light of this, we aim to determine whether ROR1 is expressed on huNSG B cells. Using flow cytometry analysis, we found that ROR1 was highly expressed in a proportion of bone marrow, spleen, and blood B cells, which were mostly immature B cells. Transplantation of the oncogene TCL-1-transduced CD34+ cells in neonatal NSG mice did not increase the frequency of ROR1-expressing B cells, but the mouse with the highest engraftment of transduced cells developed a tumor-like lump consisting of a high percentage of ROR1-expressing B cells. This study highlights the potential use of huNSG mice to study B cell malignant diseases and to evaluate immunotherapeutics targeting ROR1.
Subject(s)
B-Lymphocytes/physiology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/physiology , Immunotherapy/methods , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Proto-Oncogene Proteins/genetics , Receptor Tyrosine Kinase-like Orphan Receptors/metabolism , Animals , Antigens, CD34/metabolism , Carcinogenesis/genetics , Cell Separation , Flow Cytometry , Gene Expression Regulation, Neoplastic , Humans , Interleukin Receptor Common gamma Subunit/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Mice , Mice, Knockout , Mice, SCID , Receptor Tyrosine Kinase-like Orphan Receptors/genetics , Transplantation Chimera , Up-RegulationABSTRACT
Antigenic peptides presented by major histocompatibility complex (MHC) class II molecules are generally derived from exogenous proteins acquired by antigen presenting cells. However, in some circumstances, MHC class II molecules can present intracellular proteins expressed within the antigen-presenting cells. There are several described pathways by which endogenous antigens are degraded and gain access to MHC class II molecules. These include autophagy and other non-autophagic pathways; the latter category includes the MHC class I-like pathways, heat shock protein 90-mediated pathways, and internalization from the plasma membrane. This review will summarize and discuss the non-autophagic pathways.
ABSTRACT
The Epstein-Barr virus (EBV) is found in a variety of tumors whose incidence greatly varies around the world. A poorly explored hypothesis is that particular EBV strains account for this phenomenon. We report that M81, a virus isolated from a Chinese patient with nasopharyngeal carcinoma (NPC), shows remarkable similarity to other NPC viruses but is divergent from all other known strains. M81 exhibited a reversed tropism relative to common strains with a reduced ability to infect B cells and a high propensity to infect epithelial cells, which is in agreement with its isolation from carcinomas. M81 spontaneously replicated in B cells in vitro and in vivo at unusually high levels, in line with the enhanced viral replication observed in NPC patients. Spontaneous replication and epitheliotropism could be partly ascribed to polymorphisms within viral proteins. We suggest considering M81 and its closely related isolates as an EBV subtype with enhanced pathogenic potential.
Subject(s)
Herpesvirus 4, Human/physiology , Nasopharyngeal Neoplasms/virology , Amino Acid Sequence , Animals , B-Lymphocytes/cytology , B-Lymphocytes/virology , Carcinoma , Cells, Cultured , Epithelial Cells/cytology , Epithelial Cells/virology , Genome, Viral , HEK293 Cells , Herpesvirus 4, Human/classification , Herpesvirus 4, Human/genetics , Humans , Mice , Mice, Inbred NOD , Molecular Sequence Data , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/metabolism , Nasopharyngeal Neoplasms/pathology , Phenotype , Polymorphism, Genetic , Sequence Alignment , Sequence Homology, Amino Acid , Viral Proteins/chemistry , Viral Proteins/genetics , Viral Proteins/metabolism , Virus ReplicationABSTRACT
Primary infection with the human oncogenic Epstein-Barr virus (EBV) can result in infectious mononucleosis (IM), a self-limiting disease caused by massive lymphocyte expansion that predisposes for the development of distinct EBV-associated lymphomas. Why some individuals experience this symptomatic primary EBV infection, whereas the majority acquires the virus asymptomatically, remains unclear. Using a mouse model with reconstituted human immune system components, we show that depletion of human natural killer (NK) cells enhances IM symptoms and promotes EBV-associated tumorigenesis mainly because of a loss of immune control over lytic EBV infection. These data suggest that failure of innate immune control by human NK cells augments symptomatic lytic EBV infection, which drives lymphocyte expansion and predisposes for EBV-associated malignancies.
Subject(s)
Infectious Mononucleosis/immunology , Killer Cells, Natural/immunology , Animals , Carcinogenesis , Humans , Immunity, Innate , Immunologic Memory , Infectious Mononucleosis/pathology , Infectious Mononucleosis/prevention & control , Mice , Mice, Inbred NOD , Mice, SCID , Trans-Activators/immunologyABSTRACT
The B cell-depleting IgG1 monoclonal antibody rituximab can persistently suppress disease progression in some patients with autoimmune diseases. However, the mechanism underlying these long-term beneficial effects has remained unclear. Here, we evaluated Ig gene usage in patients with anti-myelin-associated glycoprotein (anti-MAG) neuropathy, an autoimmune disease of the peripheral nervous system that is mediated by IgM autoantibodies binding to MAG antigen. Patients with anti-MAG neuropathy showed substantial clonal expansions of blood IgM memory B cells that recognized MAG antigen. The group of patients showing no clinical improvement after rituximab therapy were distinguished from clinical responders by a higher load of clonal IgM memory B cell expansions before and after therapy, by persistence of clonal expansions despite efficient peripheral B cell depletion, and by a lack of substantial changes in somatic hypermutation frequencies of IgM memory B cells. We infer from these data that the effectiveness of rituximab therapy depends on efficient depletion of noncirculating B cells and is associated with qualitative immunological changes that indicate reconfiguration of B cell memory through sustained reduction of autoreactive clonal expansions. These findings support the continued development of B cell-depleting therapies for autoimmune diseases.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/pharmacology , Autoimmune Diseases of the Nervous System/drug therapy , B-Lymphocyte Subsets/drug effects , Immunologic Memory , Lymphocyte Depletion/methods , Aged , Autoantibodies/immunology , Autoantigens/immunology , Autoimmune Diseases of the Nervous System/immunology , Clinical Trials as Topic/statistics & numerical data , Clone Cells/immunology , Double-Blind Method , Female , Humans , Immunoglobulin M/immunology , Male , Middle Aged , Myelin-Associated Glycoprotein/immunology , Rituximab , Severity of Illness Index , Somatic Hypermutation, Immunoglobulin , Treatment OutcomeABSTRACT
CD4(+) T cells recognize peptides displayed by MHC II molecules on the surface of specialized antigen-presenting cells (APCs). These peptides are generally considered to come from exogenous proteins that have been internalized by APCs and degraded in the endocytic network, thus representing a snapshot of proteins in the APC's extracellular environment. However, it is increasingly apparent that some proteins endogenously expressed within the APC itself can directly gain access to the MHC II pathway. This has particular implications for pathogens that naturally infect APCs, since such infections might therefore become visible to CD4(+) (MHC II-restricted) effector T cells. Such a pathogen is Epstein-Barr Virus (EBV), a human herpesvirus that infects most individuals establishing life-long infection of B cells. EBV's persistence in the immune host depends upon expression of the viral nuclear protein EBNA1 to segregate the viral genome into daughter cells during homeostatic B cell turnover. Surprisingly, EBNA1 contains many CD4 epitopes, elicits strong CD4 T cell responses in most people and, in in vitro models, can be processed for CD4(+) T cell recognition through delivery into the MHC II pathway, apparently via macroautophagy (hereafter referred to as autophagy). Taken together, these observations raise the interesting question of how does EBV persist in the B cell system given the presence of strong CD4 T cell responses directed against the one protein the virus absolutely requires for long-term persistence?